Jump to content



Recommended Posts

  • Replies 13.3k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

In reply to: bunny123 on Wednesday 20/07/05 01:21pm



'Its a race against time' as they say and if more funds now can expediate the process to market whilst the US media is high and its record is flawless.. then they should strike while the irons hot.


If they can secure funds at sub 152 then the upside for the US investors is very high and please them no end and ensure their continued support whilst retaining ours. I think its prudent if they do it now rather than later.


A dilution by $50m is is nothing when you consider the market that is at stake.

Link to comment
Share on other sites

In reply to: kili on Wednesday 20/07/05 01:56pm

Also, a capital raising would create a concrete support level, which the s.p would likely approach and then surge with more conviction than any analysts valuation.

Link to comment
Share on other sites

In reply to: kili on Wednesday 20/07/05 02:07pm

If history is anything to go by, then whatever price they offer at will be the CEILING and the price will fall from there. The surge will happen beforehand. It has always fallen down from every cash raising.


Looks like the FAÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ers will need to do some recalculating when this goes through.


My opinion is I could not care less what they do as long as they do whatever it takes to get this product to market en masse ASAP ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¦. I want it selling, I want speculation on production lines and delivery times. It has been years now and still progress is good but come on get it to market, 10,000 people died waiting. (thatÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s a guess).


IÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢d also expect to see whoever takes up the offer to be a mighty strong US company with sharp teeth and an appetite for profit ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¦


Price action looks OK .. it is lunchtime, I would like to see wot I said before, close over 1.50 and better yet, a run for 1.55 ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¦ actually a close at around 1.54 would be even better because it would prime everyone for tomorrow to breakout.


Link to comment
Share on other sites

In reply to: bunny123 on Wednesday 20/07/05 01:21pm



They state that the 10 USA BTT implants will be completed by the end of 2005 thats about 2 implants a month, this should progressively get US and global attention as well as the CE trails and therefore share price action so they may just get $2.25 again or better.


The 200 implants for the other US trails will be reimbursed, so in round aussie dollars, this equates to about $20m and will reduce their capital requirements.


Personnally I would not like a partnership, VCR has already done the hard yards why give it to the yanks, this should stay an aussie product.




Link to comment
Share on other sites

In reply to: Oavde on Wednesday 20/07/05 02:29pm

Perhaps they've learn't something about investor relations since the last raising...


Getting the thing to market ASAP is there top priority and in a previous announcement said they would forgo reimbersements to achieve this....... a capital raising now means they could do this en masse.

Link to comment
Share on other sites

In reply to: kili on Wednesday 20/07/05 02:45pm

Totally agree lets follow Cochlear's example, we are now approaching the business end, the US trails will go very quickly once the first 10 have been completed successfully and publicised, because the demand is very high with 27,000 patients each year. You never know the FDA approval may come more quickly.

Link to comment
Share on other sites


Lack Of Major Heart Device Trials Hurts Sector's Luster




By Daniel Rosenberg, Of DOW JONES NEWSWIRES


CHICAGO -(Dow Jones)- Not so long ago, the heart device world was awash in important medical trials, results of which changed the way doctors practiced medicine and proved major catalysts for industry stock prices.


Today, by comparison, major trials are few and far between. The big drug- eluting stent and implantable cardioverter defibrillator, or ICD, trials that fired up investors and sent stock prices soaring are mostly in the past. As a result, stock prices have ebbed for many companies in the sector this year.


Dr. Eric Topol, chairman of the cardiology department at the Cleveland Clinic, said in a telephone interview that the heart device market is in what he calls an "evergreen" phase, meaning it's reached old-growth status.


"It's a more mature field where there isn't as much opportunity for the next big jump in evolution," Topol said. "When we went from balloons to stents, that was a revolution. There was a revolution with bi-ventricular pacing - a medical device solution for heart failure. Now those are at a mature state where they're looking for widened indications but not replacing a pre-existing approach. There aren't revolutions in sight."


The revolutions came a few years ago. There was Guidant Corp.'s (GDT) Madit II trial, which in 2002 found a much larger than expected population of patients could be helped by implantable cardioverter defibrillators. And Medtronic Inc. ( MDT) last year released results from its trial on Sudden Cardiac Death in Heart Failure, or SCD-HeFT, which expanded the ICD population even further.


At around the same time, investors kept a close watch on Johnson & Johnson's ( JNJ) Sirius and Boston Scientific Corp.'s (BSX) Taxus drug-eluting stent trials. These trials, key results of which came out in 2002 and 2003, respectively, made it clear that drug-eluting stent therapy was superior to that provided by traditional stents, and led to huge sales gains in the stent market - and gains in the stock market - for both companies.


Other trials showed how resynchronization devices made by Guidant, Medtronic and St. Jude Medical Inc. (STJ) could help heart-failure patients. Now such devices, introduced in the U.S. in 2002, make up nearly half the ICD market.


Heart Valve Effort One To Watch


Topol and others said there might be some exciting developments in the longer term, notably the effort by Edwards Lifesciences Corp. (EW) and other companies to launch a nonsurgical heart valve replacement and efforts throughout the industry to address atrial fibrillation, a heart problem that can lead to stroke or to death.


But many of those technologies are relatively far off. Some say nonsurgical valve replacement is an opportunity for the next decade, not this one.


"There are no large studies that might change practice, or get people to change referral patterns," said John Farrall, a medical device analyst with National City Private Client Group. "We have stents. We have bypass surgery. We have ICDs. We have what we have."


The lack of significant clinical trial activity is having an effect on share prices.


While some of the major heart device companies, including Medtronic and St. Jude, have seen their stocks rise in the mid-single digits percentage-wise so far this year, shares of Boston Scientific are down 22% and shares of Edwards are up just 2.5%. Shares of Guidant are down 6%, but that reflects recalls of some of the company's devices more than anything else.


By contrast, back in the early part of the decade, shares of St. Jude and Boston Scientific sizzled. St. Jude shares rose 54% in 2003, the same year that Boston Scientific shares rose 73%. Edwards shares rose 37% last year. The cardiology sector now trades at a 32% premium to the S&P 500, compared with 64% in 2001, said Mark Landy, analyst with Susquehanna Financial Group.


"Medical device stocks tend to perform best during the latter stages of unique clinical trial activity," Landy said. "Essentially, those trials open up new markets for either current or new devices, so you can add significant revenues." He said Medtronic might be one good company to invest in because it soon will launch its own drug-eluting stent and is in the midst of trials for that product. He rates Medtronic a positive and doesn't own shares. There isn't any investment banking relationship.


Boston Scientific Chief Operating Officer Paul LaViolette admits there aren't any trials going on with the potential impact of a SCD-HeFT, but disagrees that there aren't exciting trials in progress.


He cited a study called the Carotid Revascularization Endarterectomy vs. Stenting Trial, or CREST, which looks at possible benefits of minimally invasive carotid stenting. The carotid artery forms the principal supply of blood to the head and neck.


He also noted several trials underway for devices that can close patent foramen ovales, or PFOs, an opening between chambers of the heart that can lead to strokes. In addition, he noted the work on non-surgical valve replacement and repair.


"When you look at the horizon...problems associated with the shape, size and functionality of the heart pump are all being addressed with trials," LaViolette said in a telephone interview. "Every one has the potential to change the definition of the gold standard of care."


In particular, he said, stroke intervention has a chance over the next five years to be as life altering for patients as ICDs have been for heart disease.


-By Daniel Rosenberg, Dow Jones Newswires; 312-750-4118; daniel.rosenberg@ dowjones.com



Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...